Canada markets closed

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
44.71+0.34 (+0.77%)
At close: 04:00PM EDT
44.76 +0.05 (+0.11%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close44.37
Bid44.50 x 1100
Ask45.00 x 4000
Day's Range44.40 - 44.90
52 Week Range37.80 - 46.97
Avg. Volume5,160,391
Market Cap113.652B
Beta (5Y Monthly)0.37
PE Ratio (TTM)18.07
EPS (TTM)2.47
Earnings DateFeb 01, 2017 - Feb 06, 2017
Forward Dividend & Yield1.99 (4.48%)
Ex-Dividend DateMay 19, 2022
1y Target Est49.81
  • Zacks

    Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold

    Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.

  • Motley Fool

    Was This Acquisition a Smart Move for GlaxoSmithKline?

    The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.

  • Motley Fool

    Why GSK May Have Bet Too Big on a Pandemic Pipeline

    Pharmaceutical giant GlaxoSmithKline (NYSE: GSK) missed out on this early action and now looks to launch several pandemic products this year. GSK has three separate COVID vaccines in late-stage development, in various partnerships with Sanofi (NASDAQ: SNY), South Korean pharmaceutical SK bioscience, and Canadian biopharmaceutical Medicago. GSK's Phase 3 clinical trials are wrapping up, and GSK expects regulatory decisions in the US and EU starting later this year.